JP6216791B2 - 阻害剤化合物 - Google Patents
阻害剤化合物 Download PDFInfo
- Publication number
- JP6216791B2 JP6216791B2 JP2015530495A JP2015530495A JP6216791B2 JP 6216791 B2 JP6216791 B2 JP 6216791B2 JP 2015530495 A JP2015530495 A JP 2015530495A JP 2015530495 A JP2015530495 A JP 2015530495A JP 6216791 B2 JP6216791 B2 JP 6216791B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- alkyl
- methoxy
- pyrazol
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZLJIRNNOBVWOOS-UHFFFAOYSA-N C=[O]c(cc(cc1)S)c1N Chemical compound C=[O]c(cc(cc1)S)c1N ZLJIRNNOBVWOOS-UHFFFAOYSA-N 0.000 description 1
- MJSREVGITAJCEL-UHFFFAOYSA-N CC(C)(CNc1nccc2c1nc(Nc(ccc(-c1nnn[n]1C)n1)c1OC)nc2)OC Chemical compound CC(C)(CNc1nccc2c1nc(Nc(ccc(-c1nnn[n]1C)n1)c1OC)nc2)OC MJSREVGITAJCEL-UHFFFAOYSA-N 0.000 description 1
- KEJBZRCOUASHPK-UHFFFAOYSA-N CC(C)Oc(cc(cc1)-c2c[n](C)nc2)c1NC=O Chemical compound CC(C)Oc(cc(cc1)-c2c[n](C)nc2)c1NC=O KEJBZRCOUASHPK-UHFFFAOYSA-N 0.000 description 1
- KTDLIDFCMGOUKC-NSHDSACASA-N CC1(C)OB(C2=CN(CC(F)F)N(C)C2)O[C@]1(C)N Chemical compound CC1(C)OB(C2=CN(CC(F)F)N(C)C2)O[C@]1(C)N KTDLIDFCMGOUKC-NSHDSACASA-N 0.000 description 1
- 0 CCOC1=CC(c2nnc[n]2C)=CCC1Nc1nc(c(*)nc(C)c2)c2cn1 Chemical compound CCOC1=CC(c2nnc[n]2C)=CCC1Nc1nc(c(*)nc(C)c2)c2cn1 0.000 description 1
- YEOQHUXOUKTVPT-UHFFFAOYSA-N CCOc(cc(cc1)-c2nnc[n]2C)c1N Chemical compound CCOc(cc(cc1)-c2nnc[n]2C)c1N YEOQHUXOUKTVPT-UHFFFAOYSA-N 0.000 description 1
- AZOWLGREMRBIRN-UHFFFAOYSA-N CCc(cc(cc1)-c2c[n](C)nc2)c1N Chemical compound CCc(cc(cc1)-c2c[n](C)nc2)c1N AZOWLGREMRBIRN-UHFFFAOYSA-N 0.000 description 1
- PAFQTDKYYROHMA-UHFFFAOYSA-N CN(C)CC[n]1ncc(I)c1 Chemical compound CN(C)CC[n]1ncc(I)c1 PAFQTDKYYROHMA-UHFFFAOYSA-N 0.000 description 1
- YHXOZAUTEWFRER-UHFFFAOYSA-N CN(CC1)CCC1[n]1ncc(-c2cccc3c2cc(Nc(ccc(C(N(C2)CC2OC)=O)c2)c2OC)nc3)c1 Chemical compound CN(CC1)CCC1[n]1ncc(-c2cccc3c2cc(Nc(ccc(C(N(C2)CC2OC)=O)c2)c2OC)nc3)c1 YHXOZAUTEWFRER-UHFFFAOYSA-N 0.000 description 1
- UALRJETVVDVJCD-XIWNQAKTSA-O CN/C=C(\C=[NH2+])/c(cc1OC)ccc1Nc1nc(c(Cl)ncc2)c2cn1 Chemical compound CN/C=C(\C=[NH2+])/c(cc1OC)ccc1Nc1nc(c(Cl)ncc2)c2cn1 UALRJETVVDVJCD-XIWNQAKTSA-O 0.000 description 1
- XKTMLTZHDGOSNL-UHFFFAOYSA-N CN1CCN(CC[n]2ncc(-c(cc3OC)ccc3Nc3nc(c(NC4CCCCC4)ncc4)c4cn3)c2)CC1 Chemical compound CN1CCN(CC[n]2ncc(-c(cc3OC)ccc3Nc3nc(c(NC4CCCCC4)ncc4)c4cn3)c2)CC1 XKTMLTZHDGOSNL-UHFFFAOYSA-N 0.000 description 1
- KRQMSXPCFNMXGS-UHFFFAOYSA-N CN1CCN(CC[n]2ncc(I)c2)CC1 Chemical compound CN1CCN(CC[n]2ncc(I)c2)CC1 KRQMSXPCFNMXGS-UHFFFAOYSA-N 0.000 description 1
- SKSRYWGHQFQRME-UHFFFAOYSA-N COc(nc(cc1)SC)c1[N+]([O-])=O Chemical compound COc(nc(cc1)SC)c1[N+]([O-])=O SKSRYWGHQFQRME-UHFFFAOYSA-N 0.000 description 1
- RBRQRTSULICSFP-UHFFFAOYSA-N CS(c1nc2c(N3CC4(COC4)CC3)nccc2cn1)(=O)=O Chemical compound CS(c1nc2c(N3CC4(COC4)CC3)nccc2cn1)(=O)=O RBRQRTSULICSFP-UHFFFAOYSA-N 0.000 description 1
- PVHIGFHNYQVMRW-UHFFFAOYSA-N CSc1nc2c(C3CC3)nccc2cn1 Chemical compound CSc1nc2c(C3CC3)nccc2cn1 PVHIGFHNYQVMRW-UHFFFAOYSA-N 0.000 description 1
- PCTUEDXGUWSKSV-UHFFFAOYSA-N C[n](nc1)nc1C(C=CC1[N+]([O-])=O)=NC1OC Chemical compound C[n](nc1)nc1C(C=CC1[N+]([O-])=O)=NC1OC PCTUEDXGUWSKSV-UHFFFAOYSA-N 0.000 description 1
- SEROCBXXHACDIM-UHFFFAOYSA-N C[n]1ncc(-c(c2c3)cccc2cnc3Nc(ccc(OC)c2)c2OC)c1 Chemical compound C[n]1ncc(-c(c2c3)cccc2cnc3Nc(ccc(OC)c2)c2OC)c1 SEROCBXXHACDIM-UHFFFAOYSA-N 0.000 description 1
- WURIOZMXFUGBMX-UHFFFAOYSA-N C[n]1ncc(-c(cc2OC)ccc2Nc2nc(c(-c3c[n](C)nc3)ncc3)c3cn2)c1 Chemical compound C[n]1ncc(-c(cc2OC)ccc2Nc2nc(c(-c3c[n](C)nc3)ncc3)c3cn2)c1 WURIOZMXFUGBMX-UHFFFAOYSA-N 0.000 description 1
- SYXBXYLYOCLOHD-UHFFFAOYSA-N C[n]1nnnc1-c(cc1)nc(OC)c1N Chemical compound C[n]1nnnc1-c(cc1)nc(OC)c1N SYXBXYLYOCLOHD-UHFFFAOYSA-N 0.000 description 1
- ALNODCCNKFRLDE-UHFFFAOYSA-N Nc(c(Cl)c1)ccc1N1CC=[O]CC1 Chemical compound Nc(c(Cl)c1)ccc1N1CC=[O]CC1 ALNODCCNKFRLDE-UHFFFAOYSA-N 0.000 description 1
- DZMNECGHHBBVBC-UHFFFAOYSA-N Oc(c1c2)nccc1cnc2OCc1ccccc1 Chemical compound Oc(c1c2)nccc1cnc2OCc1ccccc1 DZMNECGHHBBVBC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1216017.2 | 2012-09-07 | ||
| GBGB1216017.2A GB201216017D0 (en) | 2012-09-07 | 2012-09-07 | Inhibitor compounds |
| PCT/GB2013/052360 WO2014037750A1 (en) | 2012-09-07 | 2013-09-09 | Inhibitor compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Division JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015527387A JP2015527387A (ja) | 2015-09-17 |
| JP2015527387A5 JP2015527387A5 (enExample) | 2017-09-07 |
| JP6216791B2 true JP6216791B2 (ja) | 2017-10-18 |
Family
ID=47137117
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015530495A Active JP6216791B2 (ja) | 2012-09-07 | 2013-09-09 | 阻害剤化合物 |
| JP2017182377A Active JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017182377A Active JP6496376B2 (ja) | 2012-09-07 | 2017-09-22 | 阻害剤化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US9409907B2 (enExample) |
| EP (2) | EP2892889B1 (enExample) |
| JP (2) | JP6216791B2 (enExample) |
| CN (1) | CN104837829B (enExample) |
| AU (2) | AU2013311434B2 (enExample) |
| BR (1) | BR112015004489B1 (enExample) |
| CA (1) | CA2884006C (enExample) |
| CY (1) | CY1119714T1 (enExample) |
| DK (2) | DK2892889T3 (enExample) |
| ES (2) | ES2742442T3 (enExample) |
| GB (1) | GB201216017D0 (enExample) |
| HR (1) | HRP20171835T1 (enExample) |
| HU (1) | HUE036259T2 (enExample) |
| LT (1) | LT2892889T (enExample) |
| NO (1) | NO2892889T3 (enExample) |
| PL (1) | PL2892889T3 (enExample) |
| PT (1) | PT2892889T (enExample) |
| RS (1) | RS56750B1 (enExample) |
| RU (1) | RU2673079C2 (enExample) |
| SI (1) | SI2892889T1 (enExample) |
| SM (1) | SMT201700596T1 (enExample) |
| WO (1) | WO2014037750A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018027967A (ja) * | 2012-09-07 | 2018-02-22 | キャンサー・リサーチ・テクノロジー・リミテッド | 阻害剤化合物 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9017724B2 (en) | 2004-02-24 | 2015-04-28 | The General Hospital Corporation | Catalytic radiofluorination |
| EP2268647B1 (en) | 2008-03-21 | 2017-01-25 | The General Hospital Corporation | Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| RU2718876C2 (ru) * | 2013-08-23 | 2020-04-15 | Ньюфарма, Инк. | Некоторые химические соединения, композиции и способы |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| JP6616934B2 (ja) * | 2014-05-22 | 2019-12-04 | 株式会社 資生堂 | レナリドミドの光学分割方法 |
| US10947201B2 (en) | 2015-02-17 | 2021-03-16 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| US11208696B2 (en) | 2015-04-17 | 2021-12-28 | Netherlands Translational Research Center B.V. | Prognostic biomarkers for TTK inhibitor chemotherapy |
| RU2695337C2 (ru) * | 2015-05-29 | 2019-07-23 | Тейдзин Фарма Лимитед | ПРОИЗВОДНОЕ ПИРИДО[3,4-d]ПИРИМИДИНА И ЕГО ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМАЯ СОЛЬ |
| WO2017012559A1 (zh) * | 2015-07-21 | 2017-01-26 | 广州再极医药科技有限公司 | 稠环嘧啶类化合物、中间体、其制备方法、组合物和应用 |
| GB201522532D0 (en) * | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| EP3497087B1 (en) | 2016-08-15 | 2021-11-10 | Neupharma, Inc. | Pyrrolo[1,2-c]pyrimidine, imidazo[1,5-c]pyrimidine, quinazoline, purine and imidazo[1,5-a][1,3,5]triazine derivatives as tyrosine kinase inhibitors for the treatment of cancer |
| CN109996800B (zh) | 2016-11-28 | 2021-11-19 | 帝人制药株式会社 | 吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体 |
| SI3546458T1 (sl) | 2016-11-28 | 2021-03-31 | Teijin Pharma Limited | Derivati ((piridin-2-il)-amino)pirido(3,4-d)pirimidina in ((piridazin-3-il)amino)pirido(3,4-d)pirimidina kot zaviralci CDK4/6 za zdravljenje npr. revmatoidnega artritisa, arterioskleroze, pljučne fibroze, možganske kapi ali raka |
| GB201709840D0 (en) * | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
| AU2018287988A1 (en) * | 2017-06-20 | 2019-10-10 | Breast Cancer Now | Methods and medical uses |
| EP3701304B1 (en) | 2017-10-26 | 2022-05-04 | CommScope Connectivity Belgium BVBA | Telecommunications system |
| GB201809458D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| GB201809460D0 (en) * | 2018-06-08 | 2018-07-25 | Crt Pioneer Fund Lp | Salt form |
| CA3156777A1 (en) | 2019-10-30 | 2021-05-06 | Fusheng ZHOU | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| EP4090663A1 (en) * | 2020-01-15 | 2022-11-23 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2022002118A1 (zh) * | 2020-07-01 | 2022-01-06 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| US11267788B2 (en) * | 2020-07-16 | 2022-03-08 | Dermavant Sciences GmbH | Isoquinoline compounds and their use in treating AhR imbalance |
| US20230303564A1 (en) * | 2020-08-17 | 2023-09-28 | Medshine Discovery Inc. | Pyrimidine ring compound |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| CN115583946A (zh) * | 2021-07-06 | 2023-01-10 | 赛诺哈勃药业（成都）有限公司 | 杂环化合物及其作为cdk抑制剂的用途 |
| CA3240763A1 (en) * | 2021-12-16 | 2023-06-22 | Transthera Sciences (Nanjing) , Inc. | Cdk9 inhibitor and use thereof |
| WO2024238574A1 (en) * | 2023-05-15 | 2024-11-21 | Aleksia Therapeutics, Inc. | Cdk inhibitor compounds |
| WO2025038785A1 (en) * | 2023-08-16 | 2025-02-20 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions, and therapeutic applications |
| CN117800875B (zh) * | 2023-12-21 | 2024-10-22 | 泰州精英化成医药科技有限公司 | 一种反式-(N-Boc-4-氨基环己基)乙酸的制备方法 |
| WO2025155740A1 (en) * | 2024-01-17 | 2025-07-24 | Iambic Therapeutics, Inc. | Combinations comprising aza-quinazoline compounds for use in the treatment of cancer |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2697710A (en) | 1953-01-02 | 1954-12-21 | Burroughs Wellcome Co | Pyrido (2,3-d) pyrimidines and method of preparing same |
| US3021332A (en) | 1954-01-04 | 1962-02-13 | Burroughs Wellcome Co | Pyrido (2, 3-d) pyrimidine compounds and method of making |
| AU711426B2 (en) | 1994-11-14 | 1999-10-14 | Warner-Lambert Company | 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| PA8510701A1 (es) | 2000-01-25 | 2002-12-11 | Warner Lambert Co | PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| WO2002090360A1 (en) | 2001-05-10 | 2002-11-14 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| AU2002324450A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyridopyrimidines and uses thereof |
| JP2005516927A (ja) | 2001-12-13 | 2005-06-09 | アボット・ラボラトリーズ | 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物 |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| JP4187657B2 (ja) | 2002-03-07 | 2008-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | ｐ３８キナーゼインヒビターとしての二環式ピリジン及びピリミジン |
| WO2004014907A1 (en) * | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| EP1569637A1 (en) | 2002-11-12 | 2005-09-07 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
| US20040092521A1 (en) | 2002-11-12 | 2004-05-13 | Altenbach Robert J. | Bicyclic-substituted amines as histamine-3 receptor ligands |
| MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
| US20050256118A1 (en) | 2004-05-12 | 2005-11-17 | Altenbach Robert J | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| US7098222B2 (en) | 2004-05-12 | 2006-08-29 | Abbott Laboratories | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents |
| AU2006264043B2 (en) | 2005-06-28 | 2012-04-26 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of Rho-kinase |
| ES2378473T3 (es) * | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Compuestos antivirales |
| TW200808739A (en) * | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| CA2673003A1 (en) * | 2006-12-22 | 2008-07-03 | Novartis Ag | Quinazolines for pdk1 inhibition |
| WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
| WO2009032694A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| EP2226315A4 (en) * | 2007-12-28 | 2012-01-25 | Carna Biosciences Inc | 2-aminoquinazoline DERIVATIVE |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0812969D0 (en) | 2008-07-15 | 2008-08-20 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| AU2010343102B2 (en) | 2009-12-29 | 2016-03-24 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CN102883607B (zh) | 2010-03-01 | 2015-07-22 | Gtx公司 | 用于治疗癌的化合物 |
| GB201011182D0 (en) | 2010-07-02 | 2010-08-18 | Wireless Fibre Systems Ltd | Riser wireless communications system |
| JP5997143B2 (ja) * | 2010-07-30 | 2016-09-28 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | タンパク質キナーゼ活性の調整剤としてのイソオキサゾロ−キナゾリン |
| ES2377610B1 (es) | 2010-09-01 | 2013-02-05 | Institut Químic de Sarriá CETS Fundació Privada | Preparación de compuestos pirido[2,3-d]pirimidin-7(8h)-ona sustituidos. |
| WO2012052540A1 (en) | 2010-10-21 | 2012-04-26 | Universitaet Des Saarlandes | Selective cyp11b1 inhibitors for the treatment of cortisol dependent diseases |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| CN103261167B (zh) | 2010-12-17 | 2016-05-04 | 霍夫曼-拉罗奇有限公司 | 取代的6，6-稠合含氮杂环化合物及其用途 |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| TWI450891B (zh) | 2010-12-29 | 2014-09-01 | Dev Center Biotechnology | 新穎微管蛋白抑制劑 |
| BR112013018515B1 (pt) * | 2011-01-26 | 2021-06-29 | Nerviano Medical Sciences S.R.I | Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| US9745191B2 (en) | 2011-04-11 | 2017-08-29 | Saudi Arabian Oil Company | Auto thermal reforming (ATR) catalytic structures |
| BR112014002200A2 (pt) | 2011-07-29 | 2017-03-07 | Medivation Prostate Therapeutics Inc | tratamento de câncer de mama |
| CA2850394C (en) | 2011-10-12 | 2019-05-21 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
| WO2014134169A1 (en) | 2013-02-26 | 2014-09-04 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| EP3089747A1 (en) | 2013-12-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer |
| GB201403536D0 (en) | 2014-02-28 | 2014-04-16 | Cancer Rec Tech Ltd | Inhibitor compounds |
| SG11201607448PA (en) | 2014-03-11 | 2016-10-28 | Queensland Inst Med Res | Determining cancer agressiveness, prognosis and responsiveness to treatment |
| KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
| WO2016073771A2 (en) | 2014-11-06 | 2016-05-12 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors |
| GB201522532D0 (en) | 2015-12-21 | 2016-02-03 | Cancer Rec Tech Ltd | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives |
| AU2018287988A1 (en) | 2017-06-20 | 2019-10-10 | Breast Cancer Now | Methods and medical uses |
| GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
-
2012
- 2012-09-07 GB GBGB1216017.2A patent/GB201216017D0/en not_active Ceased
-
2013
- 2013-09-09 RU RU2015112580A patent/RU2673079C2/ru active
- 2013-09-09 US US14/426,549 patent/US9409907B2/en active Active
- 2013-09-09 PL PL13760106T patent/PL2892889T3/pl unknown
- 2013-09-09 SM SM20170596T patent/SMT201700596T1/it unknown
- 2013-09-09 ES ES17192253T patent/ES2742442T3/es active Active
- 2013-09-09 NO NO13760106A patent/NO2892889T3/no unknown
- 2013-09-09 WO PCT/GB2013/052360 patent/WO2014037750A1/en not_active Ceased
- 2013-09-09 LT LTEP13760106.8T patent/LT2892889T/lt unknown
- 2013-09-09 CN CN201380057967.7A patent/CN104837829B/zh not_active Expired - Fee Related
- 2013-09-09 SI SI201330829T patent/SI2892889T1/sl unknown
- 2013-09-09 DK DK13760106.8T patent/DK2892889T3/en active
- 2013-09-09 CA CA2884006A patent/CA2884006C/en active Active
- 2013-09-09 RS RS20171314A patent/RS56750B1/sr unknown
- 2013-09-09 DK DK17192253.7T patent/DK3293183T3/da active
- 2013-09-09 PT PT137601068T patent/PT2892889T/pt unknown
- 2013-09-09 AU AU2013311434A patent/AU2013311434B2/en not_active Ceased
- 2013-09-09 HU HUE13760106A patent/HUE036259T2/hu unknown
- 2013-09-09 HR HRP20171835TT patent/HRP20171835T1/hr unknown
- 2013-09-09 EP EP13760106.8A patent/EP2892889B1/en active Active
- 2013-09-09 JP JP2015530495A patent/JP6216791B2/ja active Active
- 2013-09-09 EP EP17192253.7A patent/EP3293183B1/en active Active
- 2013-09-09 BR BR112015004489-1A patent/BR112015004489B1/pt not_active IP Right Cessation
- 2013-09-09 ES ES13760106.8T patent/ES2655194T3/es active Active
-
2016
- 2016-04-06 US US15/091,887 patent/US9890157B2/en active Active
- 2016-04-06 US US15/091,980 patent/US9834552B2/en active Active
-
2017
- 2017-09-22 JP JP2017182377A patent/JP6496376B2/ja active Active
- 2017-11-27 AU AU2017268488A patent/AU2017268488B2/en not_active Ceased
- 2017-12-29 CY CY20171101358T patent/CY1119714T1/el unknown
-
2018
- 2018-01-08 US US15/864,499 patent/US10479788B2/en active Active
-
2019
- 2019-10-10 US US16/598,717 patent/US11046688B2/en not_active Expired - Fee Related
-
2021
- 2021-05-13 US US17/319,231 patent/US11897877B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018027967A (ja) * | 2012-09-07 | 2018-02-22 | キャンサー・リサーチ・テクノロジー・リミテッド | 阻害剤化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6216791B2 (ja) | 阻害剤化合物 | |
| JP6027989B2 (ja) | Ｍｐｓ１阻害剤としてのピロロピリジンアミノ誘導体 | |
| JP6297570B2 (ja) | 薬理活性化合物 | |
| JP6440728B2 (ja) | Ｎ２−フェニル−ピリド［３，４−ｄ］ピリミジン−２，８−ジアミン誘導体およびｍｐｓ１阻害剤としてのそれらの使用 | |
| HK1211921B (en) | Inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160707 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170420 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170425 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20170725 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170825 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170925 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6216791 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |